Currently out of the existing stock ratings of Sara Nik, 6 are a BUY (100%).

Sara Nik

Work Performance Price Targets & Ratings Chart

Analyst Sara Nik, carries an average stock price target met ratio of 25% that have a potential upside of 29.02% achieved within 50 days.

Sara Nik’s has documented 12 price targets and ratings displayed on 2 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on CRIS, Curis at 16-Aug-2026.

Wall Street Analyst Sara Nik

Analyst best performing recommendations are on MBRX (MOLECULIN BIOTECH).
The best stock recommendation documented was for MBRX (MOLECULIN BIOTECH) at 9/10/2025. The price target of $4 was fulfilled within 99 days with a profit of $5.53 (58.03%) receiving and performance score of 5.86.

Average potential price target upside

MBRX Moleculin Biotech CRIS Curis

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 10-Sep-2025

$22

$18.73 (572.78%)

$4

Show more analysts

Please expand the browser size to see the chart

Which stock is Sara Nik is most bullish on?

Potential upside of $41.2 has been obtained for CRIS (CURIS)

Which stock is Sara Nik is most reserved on?

Potential downside of $19.88 has been obtained for MBRX (MOLECULIN BIOTECH)

What Year was the first public recommendation made by Sara Nik?

On 2025

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?